NDLI: Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.

Please wait, while we are loading the content...

Year: 2017 Volume: 5

Year: 2016 Volume: 4

Year: 2015 Volume: 3

Year: 2014 Volume: 2

Year: 2014 Volume: 2 Issue: 11

Year: 2014 Volume: 2 Issue: 10

Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases.

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.

Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.

Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study.

Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study

Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial.

Year: 2014 Volume: 2 Issue: 9

Year: 2014 Volume: 2 Issue: 8

Year: 2014 Volume: 2 Issue: 7

Year: 2014 Volume: 2 Issue: 6

Year: 2014 Volume: 2 Issue: 5

Year: 2014 Volume: 2 Issue: 4

Year: 2014 Volume: 2 Issue: 3

Year: 2014 Volume: 2 Issue: 2

Year: 2014 Volume: 2 Issue: 1

Year: 2013 Volume: 1

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	McMurray, John J. V. Gerstein, Hertzel C. Holman, Rury R. Pfeffer, Marc A.
Description	Author Affiliation: McMurray JJ ( BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Electronic address: john.mcmurray@glasgow.ac.uk.); Gerstein HC ( Department of Medicine and Department of Clinical Epidemiology and Biostatistics, McMaster University and Population Health Research Institute, Hamilton, ON, Canada.); Holman RR ( Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.); Pfeffer MA ( Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.)
Abstract	In patients with type 1 or type 2 diabetes, glycaemic exposure assessed as HbA1c correlates strongly with risk of future microvascular and macrovascular complications. Improved glucose control substantially reduces the risk of microvascular complications and, with extended follow-up, modestly reduces the risk of atherosclerotic events. The lowering of HbA1c concentrations by newly developed glucose-lowering drugs (alone or when added to other glucose-lowering drugs) has been used, until recently, as a surrogate measure of their potential to lower cardiovascular risk. This assumption is no longer acceptable, and now demonstration of cardiovascular safety has been mandated by regulatory authorities. A major concern, however, is the universal absence in any large-scale trials of new glucose-lowering drugs of hospital admission for heart failure as a prespecified component of the primary composite cardiovascular outcomes. This omission is important because hospital admission for heart failure is a common and prognostically important cardiovascular complication of diabetes. Moreover, it is the one cardiovascular outcome for which the risk has been shown unequivocally to be increased by some glucose-lowering therapies. As such, we believe that heart failure should be systematically evaluated in cardiovascular outcome trials of all new glucose-lowering drugs.
File Format	HTM / HTML
ISSN	22138587
Issue Number	10
Volume Number	2
e-ISSN	22138595
Journal	The Lancet Diabetes & Endocrinology
Language	English
Publisher	Elsevier
Publisher Date	2014-10-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Endocrinology Diabetes Mellitus, Type 1 Complications Diabetes Mellitus, Type 2 Heart Failure Epidemiology Etiology Adult Aged Aged, 80 And Over Drug Therapy Chemically Induced Humans Hypoglycemic Agents Adverse Effects Middle Aged Risk Factors Young Adult Journal Article
Content Type	Text
Resource Type	Article
Subject	Endocrinology, Diabetes and Metabolism Internal Medicine Endocrinology

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in